Patents by Inventor Sheila DeWitt

Sheila DeWitt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
    Patent number: 11918569
    Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Grant
    Filed: August 13, 2021
    Date of Patent: March 5, 2024
    Assignee: Poxel SA
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-3-deuteropiperidine-2,6-dione derivatives and compositions comprising and methods of using the same
    Patent number: 11820720
    Abstract: The invention provides 3-deuterium-enriched 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-diones, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same, such as in the treatment of cancer, an immune-related disease, or an inflammatory disease.
    Type: Grant
    Filed: May 18, 2021
    Date of Patent: November 21, 2023
    Assignee: Salarius Pharmaceuticals, Inc.
    Inventor: Sheila DeWitt
  • Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same
    Patent number: 11773080
    Abstract: The invention provides deuterium-enriched isoindolinonyl-azepanediones, deuterium-enriched oxoquinazolin-3(4H)-yl-azepanediones, related compounds, pharmaceutical compositions, and methods of using such compounds and pharmaceutical compositions to treat cancer, angiogenesis disorders, immune disorders, and other medical disorders.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: October 3, 2023
    Assignee: Salarius Pharmaceuticals, Inc.
    Inventors: Sheila DeWitt, Vincent Jacques
  • 3-(SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTERO-PIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
    Publication number: 20230277539
    Abstract: The invention provides 3-deuterium-enriched 3-(6-, 7-, or 8-substituted-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-diones, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Application
    Filed: October 4, 2022
    Publication date: September 7, 2023
    Inventor: Sheila DeWitt
  • DEUTERIUM-ENRICHED PIPERIDINONYL-OXOISOINDOLINYL ACETAMIDES AND METHODS OF TREATING MEDICAL DISORDERS USING SAME
    Publication number: 20230242504
    Abstract: The invention provides deuterium-enriched piperidinonyl-oxoisoindolinyl acetamide compounds, pharmaceutical compositions, and methods of using such compounds and pharmaceutical compositions to treat cancer, angiogenesis disorders, immune disorders, and other medical disorders.
    Type: Application
    Filed: October 4, 2022
    Publication date: August 3, 2023
    Inventor: Sheila DeWitt
  • COMBINATION THERAPY USING ENANTIOPURE, OXY-SUBSTITUTED, DEUTERIUM-ENRICHED 5-(BENZYL)-5-DEUTERO-THIAZOLIDINE-2,4-DIONES FOR TREATMENT OF MEDICAL DISORDERS
    Publication number: 20230218595
    Abstract: The invention provides combination therapy using enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating nonalcoholic steatohepatitis, diabetes, fibrotic disorders, and other disorders using the combination therapy.
    Type: Application
    Filed: August 8, 2022
    Publication date: July 13, 2023
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • CRYSTALLINE FORMS OF DEUTERIUM-ENRICHED PIOGLITAZONE
    Publication number: 20230074827
    Abstract: Provided herein are crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof. Also provided herein are methods of using the crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof.
    Type: Application
    Filed: March 31, 2022
    Publication date: March 9, 2023
    Inventors: Laure Françoise Valérie Navarre, Emeline Gardette, Sébastien Bolze, Sheila DeWitt, Vincent Jacques
  • Deuterium-enriched piperidinonyl-oxoisoindolinyl acetamides and methods of treating medical disorders using same
    Patent number: 11535603
    Abstract: The invention provides deuterium-enriched piperidinonyl-oxoisoindolinyl acetamide compounds, pharmaceutical compositions, and methods of using such compounds and pharmaceutical compositions to treat cancer, angiogenesis disorders, immune disorders, and other medical disorders.
    Type: Grant
    Filed: August 13, 2020
    Date of Patent: December 27, 2022
    Assignee: DeuteRx, LLC
    Inventor: Sheila DeWitt
  • 5-DEUTERO-THIAZOLIDINE-2,4-DIONE COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME
    Publication number: 20220362220
    Abstract: The invention provides deuterium-enriched thiazolidine-2,4-dione compounds (i.e., deuterium-enriched glitazone compounds), enantiopure forms of deuterium-enriched glitazone compounds, pharmaceutical compositions, and methods of treating medical disorders, such as a metabolic disorder, neurological disorder, cancer, or other disorder using deuterium-enriched glitazone compounds, which are preferably in enantiopure form.
    Type: Application
    Filed: November 11, 2020
    Publication date: November 17, 2022
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • 3-(substituted-4-oxoquinazolin-3(4)-yl)-3-deutero-piperidine-2,6-dione derivatives and compositions comprising and methods of using the same
    Patent number: 11491156
    Abstract: The invention provides 3-deuterium-enriched 3-(6-, 7-, or 8-substituted-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-diones, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Grant
    Filed: December 17, 2019
    Date of Patent: November 8, 2022
    Assignee: DeuteRx, LLC
    Inventor: Sheila DeWitt
  • METHODS OF TREATING NEUROLOGICAL AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED BUPROPION
    Publication number: 20220213023
    Abstract: The invention provides enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched bupropion. A preferred aspect of the invention provides methods of treating obesity and sexual dysfunction using enantiopure deuterium-enriched bupropion.
    Type: Application
    Filed: March 10, 2022
    Publication date: July 7, 2022
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus H.T. van der Ploeg
  • 5-DEUTERO-2,4-THIAZOLIDINEDIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
    Publication number: 20220211682
    Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Application
    Filed: August 13, 2021
    Publication date: July 7, 2022
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • METHODS OF TREATING NEUROLOGICAL, METABOLIC, AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED PIOGLITAZONE
    Publication number: 20220193055
    Abstract: The invention provides enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating neurological disorders, cancer, respiratory disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched pioglitazone. A preferred aspect of the invention provides methods of treating Alzheimer's disease, non-small cell lung cancer, hepatocellular carcinoma, and chronic obstructive pulmonary disease using enantiopure deuterium-enriched pioglitazone.
    Type: Application
    Filed: August 5, 2021
    Publication date: June 23, 2022
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • Crystalline forms of deuterium-enriched pioglitazone
    Patent number: 11319313
    Abstract: Provided herein are crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof. Also provided herein are methods of using the crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof.
    Type: Grant
    Filed: May 7, 2021
    Date of Patent: May 3, 2022
    Assignee: Poxel SA
    Inventors: Laure Françoise Valérie Navarre, Emeline Gardette, Sébastien Bolze, Sheila DeWitt, Vincent Jacques
  • 3-(5-SUBSTITUTED-4-OXOQUINAZOLIN-3(4H)-YL)-3-DEUTEROPIPERIDINE-2,6-DIONE DERIVATIVES AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME
    Publication number: 20220098128
    Abstract: The invention provides 3-deuterium-enriched 3-(5-substituted-4-oxoquinazolin-3(4H)-yl)-piperidine-2,6-diones, deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same, such as in the treatment of cancer, an immune-related disease, or an inflammatory disease.
    Type: Application
    Filed: May 18, 2021
    Publication date: March 31, 2022
    Inventor: Sheila DeWitt
  • CRYSTALLINE FORMS OF DEUTERIUM-ENRICHED PIOGLITAZONE
    Publication number: 20210403464
    Abstract: Provided herein are crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof. Also provided herein are methods of using the crystalline forms of deuterium-enriched (R)-pioglitazone and compositions thereof.
    Type: Application
    Filed: May 7, 2021
    Publication date: December 30, 2021
    Inventors: Laure Françoise Valérie Navarre, Emeline Gardette, Sébastien Bolze, Sheila DeWitt, Vincent Jacques
  • METHODS OF TREATING NEUROLOGICAL AND OTHER DISORDERS USING ENANTIOPURE DEUTERIUM-ENRICHED BUPROPION
    Publication number: 20210387940
    Abstract: The invention provides enantiopure deuterium-enriched bupropion, pharmaceutical compositions, and methods of treating neurological disorders, movement disorders, cardiovascular disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched bupropion. A preferred aspect of the invention provides methods of treating obesity and sexual dysfunction using enantiopure deuterium-enriched bupropion.
    Type: Application
    Filed: January 26, 2021
    Publication date: December 16, 2021
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus H.T. van der Ploeg
  • DEUTERIUM-ENRICHED ISOINDOLINONYL-AZEPANEDIONES AND RELATED COMPOUNDS AND METHODS OF TREATING MEDICAL DISORDERS USING SAME
    Publication number: 20210340125
    Abstract: The invention provides deuterium-enriched isoindolinonyl-azepanediones, deuterium-enriched oxoquinazolin-3(4H)-yl-azepanediones, related compounds, pharmaceutical compositions, and methods of using such compounds and pharmaceutical compositions to treat cancer, angiogenesis disorders, immune disorders, and other medical disorders.
    Type: Application
    Filed: December 21, 2018
    Publication date: November 4, 2021
    Inventors: Sheila DeWitt, Vincent Jacques
  • Methods of treating neurological, metabolic, and other disorders using enantiopure deuterium-enriched pioglitazone
    Patent number: 11141411
    Abstract: The invention provides enantiopure deuterium-enriched pioglitazone, pharmaceutical compositions, and methods of treating neurological disorders, cancer, respiratory disorders, metabolic disorders, and other disorders using enantiopure deuterium-enriched pioglitazone. A preferred aspect of the invention provides methods of treating Alzheimer's disease, non-small cell lung cancer, hepatocellular carcinoma, and chronic obstructive pulmonary disease using enantiopure deuterium-enriched pioglitazone.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: October 12, 2021
    Assignee: Poxel SA
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg
  • 5-deutero-2,4-thiazolidinedione derivatives and compositions comprising and methods of using the same
    Patent number: 11123336
    Abstract: The invention provides 5-deuterium-enriched 2,4-thiazolidinediones (e.g., 5-[4-[2-(5-ethyl-2-pyridyl)-2-oxoethoxy]benzyl]-5-deutero-thiazolidine-2,4-dione), deuterated derivatives thereof, stereoisomers thereof, pharmaceutically acceptable salt forms thereof, and methods of treatment using the same.
    Type: Grant
    Filed: March 5, 2019
    Date of Patent: September 21, 2021
    Assignee: Poxel SA
    Inventors: Sheila DeWitt, Vincent Jacques, Leonardus van der Ploeg